Takeda Pharmaceutical Company

Over Three Years after Receiving a Complete Response Letter From the FDA, Takeda's Subcutaneous Formulation of Entyvio (Entyvio SC) is Poised to Enter a Rapidly Evolving UC Market, According to Spherix Global Insights

Retrieved on: 
Friday, May 5, 2023
Takeda Pharmaceutical Company, Pressure, Injection, NASA RealWorld-InWorld Engineering Design Challenge, Risankizumab, EU, IV, TNF, Face, Takeda, JAK, SC, Mirikizumab, Eli Lilly and Company, Janssen, Ulcerative colitis, Traction, Patient, AbbVie, Physician, Need for Speed, CRL, BMS, Biosimilar, FDA, RealTime, Pharmaceutical industry, IL-23, Vedolizumab, Pfizer, Upadacitinib, Ustekinumab, UC

EXTON, Pa., May 4, 2023 /PRNewswire/ -- In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab). The intravenous (IV) formulation of Entyvio is the only non-TNF UC therapy which enjoys a substantial share of advanced treated patients, and the highest share of any single brand.

Key Points: 
  • EXTON, Pa., May 4, 2023 /PRNewswire/ -- In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab).
  • The intravenous (IV) formulation of Entyvio is the only non-TNF UC therapy which enjoys a substantial share of advanced treated patients, and the highest share of any single brand.
  • In the race to capture second-line UC patients, Janssen's Stelara (approved for UC in 2019) is currently favored by physicians.
  • Spherix will be monitoring the potential Entyvio SC US launch and the evolving UC market through its RealTime Dynamix™ advisory service.

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting

Retrieved on: 
Thursday, April 27, 2023
Seizure, LGS, Ovid, Participation, Takeda, Somnolence, Epilepsy, AAN, Lennox–Gastaut syndrome, COVID-19, American Academy, Dravet syndrome, Appetite, DS, Convulsion, Incidence, Patient, BID, DEE, American Academy of Neurology, Safety, Takeda Pharmaceutical Company, SLC6A1 epileptic encephalopathy, Pharmaceutical industry

Ovid maintains a significant financial interest in soticlestat, including potential milestones payments and royalties, if soticlestat receives regulatory approval and is commercialized.

Key Points: 
  • Ovid maintains a significant financial interest in soticlestat, including potential milestones payments and royalties, if soticlestat receives regulatory approval and is commercialized.
  • The interim analysis of ENDYMION 1 presented at AAN included 47 patients with DS and 83 patients with LGS.
  • Soticlestat demonstrated a sustained reduction in frequency of convulsive (DS) and drop (LGS) seizures from baseline up to 2 years.
  • At the AAN meeting, Takeda additionally presented post-hoc analysis data from the Phase 2 ELEKTRA study, which evaluated the efficacy of treatment with soticlestat by seizure type in patients with DS or LGS.

Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations

Retrieved on: 
Wednesday, April 26, 2023
Surgeon, Surgery, Takeda, GTCR, TAK, TachoSil, Takeda Pharmaceutical Company, Francisco Corzas, Acquisition, FDI, Patient, Maggot therapy, Growth, Health, Pharmaceutical industry

WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company (TSE:4502/NYSE:TAK) (“Takeda”) to acquire the TachoSil manufacturing operations in Linz, Austria. Corza Medical had previously acquired the commercial product rights for TachoSil, a best-in-class surgical patch trusted by medical professionals worldwide, in January 2021. Corza Medical shares Takeda’s commitment to patient care and has the experience and resources to continue investing in TachoSil for the benefit of patients. 

Key Points: 
  • WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company (TSE:4502/NYSE:TAK) (“Takeda”) to acquire the TachoSil manufacturing operations in Linz, Austria.
  • Corza Medical had previously acquired the commercial product rights for TachoSil , a best-in-class surgical patch trusted by medical professionals worldwide, in January 2021.
  • Corza Medical shares Takeda’s commitment to patient care and has the experience and resources to continue investing in TachoSil for the benefit of patients.
  • “We look forward to welcoming the Takeda TachoSil operations team to Corza Medical to support our investment in expanding manufacturing capacity, testing systems, and R&D facilities to develop new Biosurgery offerings,” said Tom Testa, Corza Medical Chief Executive Officer.

ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer

Retrieved on: 
Monday, April 24, 2023
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, BS, Senior, Hereditary angioedema, Takeda, Cancer, Babson College, Atopic dermatitis, MBA, ImmunoGen, IMGN, Mirvetuximab soravtansine, HAE, Acquisition, Patient, Physician, Executive Committee, ADC, Prurigo nodularis, Spacecraft, Rare, Ovarian cancer, Neurology, Takeda Pharmaceutical Company, Vaccine, EU

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
  • "We are excited to welcome Isabel to ImmunoGen's Executive Committee to lead our best-in-class commercial organization at this important moment for the company.
  • Before Shire, she worked in commercial, business strategy, and product launch positions at Forest Labs, Bionevia Pharmaceuticals, and Sunovion Pharmaceuticals.
  • "I am delighted to join ImmunoGen during this exciting time in its evolution into a commercial organization," said Ms. Kalofonos.

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

Retrieved on: 
Tuesday, April 18, 2023
Partnership, TAK, Takeda Pharmaceutical Company, New Drug Application, NDA, Paclitaxel, Incidence, HKEX, Patient, Cancer, National Medical Products Administration, Stomach cancer, Eli Lilly and Company, Mortality, Phase, Stomach, NYSE, Disease, Pharmaceutical industry

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towards addressing the significant unmet medical need for gastric cancer patients.

Key Points: 
  • Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towards addressing the significant unmet medical need for gastric cancer patients.
  • Gastric cancer is one of the most common cancers globally, with the highest incidence and mortality rates found in Asian populations.
  • China alone accounts for over 40% of all new gastric cancer cases in the world.
  • In China, fruquintinib is approved under the brand name ELUNATE® and is included in the China National Reimbursement Drug List (“NRDL”).

Armis Announces Significant Business Momentum in Healthcare

Retrieved on: 
Monday, April 17, 2023
Hardware, IOT (Internet of Things), Security, Data Management, Other Health, Technology, Pharmaceutical, Managed Care, General Health, Medical Devices, Hospitals, Software, Internet, Health, Medical Supplies, Knowledge, OT, Database, HDOS, Nuvance Health, Prevalence, Culture, Internet of things, Burke Rehabilitation Hospital, Main Line Health, Quadrant, Health care, CISO, Mater Misericordiae University Hospital, HIMSS, Organization, IoMT, POV, Risk, ARR, CIO, FDA, Environment, Takeda Pharmaceutical Company, Nursing, Cryptocurrency, Pharmaceutical industry, Medical device, Risk management, United States Army Command, Control, Communication, Computers, Cyber, Intelligence, Surveillance and Reconnaissance Center

HIMSS – Armis , the leading asset visibility and security company, today announced significant business momentum in the healthcare sector driven by healthcare and life sciences companies choosing the Armis Platform to identify and secure their medical devices.

Key Points: 
  • HIMSS – Armis , the leading asset visibility and security company, today announced significant business momentum in the healthcare sector driven by healthcare and life sciences companies choosing the Armis Platform to identify and secure their medical devices.
  • Over the past year, Armis has continued to grow its partnerships with new customers across the healthcare sector, resulting in 115% customer growth year-over-year, on average.
  • “Our work in the healthcare sector is critically important,” said Yevgeny Dibrov, CEO and Co-founder of Armis.
  • Additionally, Armis was recognized as a Hot Company in Healthcare IoT Security in Cyber Defense Magazine’s Global InfoSec Awards.

Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer

Retrieved on: 
Tuesday, April 11, 2023
HIV Medicine, University, Moses Austin, HIV, SARS-CoV-2, Infection, Shingles, CDC, RSV, MD, Patient, Tropical medicine, Chronic pain, Fellow, Panama, Hygiene, HBV, HCV, London School of Hygiene and Tropical Medicine, Takeda Pharmaceutical Company, Pharmaceutical industry, Vaccine, Ćurevo, Medicine

Guy De La Rosa has joined the company as its new Chief Medical Officer.

Key Points: 
  • Guy De La Rosa has joined the company as its new Chief Medical Officer.
  • “The Curevo team is excited to welcome Dr. De La Rosa to the company,” said George Simeon, Curevo’s CEO.
  • Upon completion of his Infectious Diseases Fellowship, Dr. De La Rosa completed a Fellowship in HIV Medicine at the University of Texas.
  • Dr. De La Rosa also holds a degree in Tropical Medicine from the London School of Hygiene & Tropical Medicine in the UK.

Pharmaceutical Multinationals Continue To Spurn The Opportunity To Connect Via Social Media At A Local Level

Retrieved on: 
Thursday, April 13, 2023
Consulting, Technology, Professional Services, Other Health, Other Communications, Health, Public Relations, Investor Relations, Pharmaceutical, Communications, Social Media, Apps, Applications, Astellas Pharma, Roche, Overalls, Lonza, HOW, Janssen, MCI Inc., Language, Express, Canonical form, Novartis, AbbVie, Novo Nordisk, Beckers, Sanofi, DEI, ESG, Takeda Pharmaceutical Company, ROI, Social media, Pfizer, Fine chemical, Sales, Marketing, TikTok, App, Merck

Serge Beckers, chairman of Worldcom Healthcare, said: “While the use of social media continues to increase, pharmaceutical firms continue to miss out on local engagement.

Key Points: 
  • Serge Beckers, chairman of Worldcom Healthcare, said: “While the use of social media continues to increase, pharmaceutical firms continue to miss out on local engagement.
  • App use has increased but visual platforms like YouTube and TikTok and mainstream social media platforms like Facebook, remain underutilized at a local level.
  • Pharma companies are missing the opportunity to convey, at a local level, how they satisfy heightened consumer expectations around topics such as DEI and ESG.
  • While all but two of the companies have a ‘global blog’, local blogs remain hard to find.

Visus Therapeutics Appoints Ophthalmology Industry Expert Jehan Tamboowalla to Senior Vice President of Business Development and Marketing

Retrieved on: 
Wednesday, April 12, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Spark Therapeutics, GSK, Therapy, Marketing, Eye, Bausch & Lomb, Bayer, Ophthalmology, Acquisition, Novartis, Patient, Takeda Pharmaceutical Company, Pharmaceutical industry, Visu

Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, today announced Jehan Tamboowalla joined the company as senior vice president of business development and marketing.

Key Points: 
  • Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, today announced Jehan Tamboowalla joined the company as senior vice president of business development and marketing.
  • “We are pleased to welcome Jehan to the Visus leadership team as we approach exciting company milestones,” said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics.
  • Prior to joining Visus, he served as Vice President, Head of New Products, Ophthalmology at Novartis.
  • Jehan continues to coach and mentor future industry leaders and speak at ophthalmology industry forums on emerging innovation and commercial strategy.

Ochre Bio Strengthens Leadership Team and Board of Directors with Liver Disease Translational Expertise

Retrieved on: 
Thursday, April 6, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Yale University, Trinity College, Conditional sentence, Abstract, Gastroenterology, NIBR, Internal medicine, Hepatology, Takeda, Bio, SSB, Financial management, Physiology, Postgraduate diploma, Biomedical Research, RNA, Quality, Doctor of Philosophy, Translation, Harvard Medical School, Trinity College Dublin, Development, Novartis, MD, Patient, BWH, Liver, Chronic liver disease, SVP, GI, Takeda Pharmaceutical Company, Management, Pharmaceutical industry, Nursing, Dietary supplement, Pharmacy, Brigham, Chinwe

Ochre Bio, an innovator in chronic liver disease medicine development, is pleased to announce the appointment of David Coughlan, PhD as VP of Translational Development and Chinwe Ukomadu, MD, PhD as an Observer on its Board of Directors.

Key Points: 
  • Ochre Bio, an innovator in chronic liver disease medicine development, is pleased to announce the appointment of David Coughlan, PhD as VP of Translational Development and Chinwe Ukomadu, MD, PhD as an Observer on its Board of Directors.
  • Dr. Coughlan will be responsible for translating the findings from Ochre Bio’s discovery platform and human-based translational models into RNA therapies ready for clinical development.
  • “Ochre’s end-to-end RNA therapy development, which includes testing in live human donor livers, is an ambitious and bold approach to tackling chronic disease.
  • I look forward to working with both the SSB and the Board to guide Ochre Bio on their path towards impacting patient lives.